LAB — Standard Biotools Income Statement
0.000.00%
Last trade - 00:00- $654.76m
- $247.43m
- $106.34m
- 49
- 33
- 52
- 41
Annual income statement for Standard Biotools, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 117 | 138 | 131 | 97.9 | 106 |
| Cost of Revenue | |||||
| Gross Profit | 64.3 | 83.3 | 69.4 | 37.1 | 50.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 181 | 189 | 198 | 214 | 183 |
| Operating Profit | -63.9 | -51 | -67.5 | -116 | -76.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -66.7 | -54.1 | -63.7 | -193 | -74.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -64.8 | -53 | -59.2 | -190 | -74.7 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -64.8 | -53 | -59.2 | -190 | -74.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -64.8 | -53 | -59.2 | -190 | -74.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.853 | -0.736 | -0.782 | -2.31 | -0.832 |